SCHEMBL30859159

SCHEMBL30859159

CC(C)[C@H](NC(=O)OC(C)(C)C)C(=O)OC(C)(C)CCN

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 3/20 0.50
▸ CTSS P25774 2/20 0.50
▸ CA2 P00918 3/20 0.46
▸ CA1 P00915 2/20 0.46
▸ CA7 P43166 2/20 0.46
▸ CTSL P07711 2/20 0.43
▸ CTSB P07858 1/20 0.43
▸ CYP2D6 P10635 1/20 0.42
▸ PREP P48147 1/20 0.41
▸ TRPA1 O75762 2/20 0.40
▸ PSENEN Q9NZ42 1/20 0.40
▸ KLK5 Q9Y337 1/20 0.40
▸ CA4 P22748 1/20 0.36
▸ CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23260554 0.84 CTSK (0.57) CTSKCTSSCA2CA1CA7
SCHEMBL24097648 0.83 CTSK (0.51) CTSKCTSSCA2CA1CA7
Ethylenediamine SCHEMBL29152184 0.80 CTSK (0.57) CTSKCTSSCA2CA1CA7
Ethylenediamine SCHEMBL29152187 0.80 CTSK (0.57) CTSKCTSSCA2CA1CA7
SCHEMBL21444852 0.79 CTSK (0.53) CTSKCTSSCA2CA1CA7
SCHEMBL3125029 0.79 CTSK (0.50) CTSKCTSSCA2CA1CA7
SCHEMBL28490772 0.79 CTSK (0.50) CTSKCTSSCA2CA1CA7
SCHEMBL247552 0.79 CTSK (0.55) CTSKCTSSCA2CA1CA7
SCHEMBL8807250 0.79 CTSK (0.55) CTSKCTSSCA2CA1CA7
SCHEMBL1505521 0.79 CTSK (0.55) CTSKCTSSCA2CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619037-A1 SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT Lerchen, Hans-Georg (DE) 2025-09-24 — — EP disclosed
WO-2024105197-A1 SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT VINCERX PHARMA GMBH (DE) 2024-05-23 — — WO disclosed
Send feedback